Loading...
By Kelly Young
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The CDC has published guidance on administering a new hexavalent vaccine to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B infection (DTaP-IPV-Hib-HepB). The three-dose Vaxelis vaccine was approved in 2018 but is not expected to be available in the U.S. until 2021.
The vaccine is indicated for use in infants at ages 2, 4, and 6 months and is licensed for use in children aged 6 weeks through 4 years.
It counts as the first three doses of the DTaP vaccine; it should not be given as the fourth or fifth dose. In addition, a fourth dose of IPV must be given separately to protect against polio, and a booster dose of Hib conjugate vaccine must also be given.
When needed, DTaP-IPV-Hib-HepB can be administered in a catch-up schedule for children under age 5 years.
Of note, the observed rate of fever was higher with this combination vaccine than with the DTaP-IPV/Hib pentavalent vaccine (roughly 47% vs. 34%).
Comment
LINK(S):
MMWR article (Free)
Background: NEJM Journal Watch Pediatrics and Adolescent Medicinecoverage of trial of hexavalent vaccine (Free)